BioStock: Annexin wants to treat the inconspicuous eye disease

Retinal vein occlusion, RVO, is one of the most common causes of vision loss in the world – yet it is unknown to many. The disease is based, as the name suggests, on a narrowing of the vein in the eye – and the condition is, despite its prevalence, unfortunately still undertreated. The biotech company Annexin Pharmaceuticals, which is well aware of this problem, wants to offer a completely new treatment strategy for the large number of affected patients with the candidate ANXV.

Read the full article about Annexin Pharmaceuticals at biostock.se:

https://www.biostock.se/en/2022/07/annexin-wants-to-treat-the-inconspicuous-eye-disease/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/